Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer's disease patients measured using [18F] THK-5351

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Lockhart, Samuel N ^a   Baker, Suzanne L ^a,b   Okamura, Nobuyuki ^c   Furukawa, Katsutoshi ^d   Ishiki, Aiko ^d   Furumoto, Shozo ^d   Tashiro, Manabu ^d   Yanai, Kazuhiko ^c,d   Arai, Hiroyuki ^d   Kudo, Yukitsuka ^d   Harada, Ryuichi ^d   Tomita, Naoki ^d   Hiraoka, Kotaro ^d   Watanuki, Shoichi ^d   Jagust, William J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN; THK 5351; TRACER; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; BIOLOGICAL MARKER; FLUORINE; MAPT PROTEIN, HUMAN; QUINOLINE DERIVATIVE; THK5351;

AGED; ALZHEIMER DISEASE; ANALYTICAL PARAMETERS; ARTICLE; BASAL GANGLION; BRAIN REGION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG BINDING; DRUG UPTAKE; ENTORHINAL CORTEX; FRONTAL CORTEX; FUSIFORM GYRUS; GRAY MATTER; HUMAN; MIDDLE TEMPORAL GYRUS; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARAHIPPOCAMPAL GYRUS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; STANDARDIZED UPTAKE VALUE RATIO; TEMPOROPARIETAL REGION; VERY ELDERLY; VOLUME OF DISTRIBUTION RATIO; BRAIN; BRAIN MAPPING; CASE CONTROL STUDY; CHEMISTRY; DIAGNOSTIC IMAGING; FRONTAL LOBE; METABOLISM; PROCEDURES; TEMPORAL LOBE; TIME FACTOR;

AGED; ALZHEIMER DISEASE; AMINOPYRIDINES; BIOMARKERS; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; COGNITION; FLUORINE RADIOISOTOPES; FRONTAL LOBE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; TAU PROTEINS; TEMPORAL LOBE; TIME FACTORS;

EID: 84977263084     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158460     Document Type: Article

References (23)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. PMID: 1759558
2. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014 Dec; 128(6):755-66. doi: 10.1007/s00401-014-1349-0 PMID: 25348064
3. Selkoe DJ, Ihara Y, Salazar FJ. Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Science. 1982 Mar 5; 215(4537):1243-5. PMID: 6120571
4. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006 Oct; 112(4):389-404. PMID: 16906426
5. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a006189. doi: 10.1101/cshperspect.a006189 PMID: 22229116
6. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb; 12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0 PMID: 23332364
7. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012 May; 71(5):362-81. doi: 10.1097/NEN.0b013e31825018f7 PMID: 22487856
8. Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009 Mar; 66(3):382-9. doi: 10.1001/archneurol.2008.596 PMID: 19273758
9. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014 Nov; 14(11):500. doi: 10.1007/s11910-014-0500-6 PMID: 25239654
10. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015 Jan; 14(1):114-24. doi: 10.1016/S1474-4422(14)70252-2 PMID: 25496902
11. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006 Dec 21; 355(25):2652-63. PMID: 17182990
12. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alz Dis. 2013; 34(2):457-68.
13. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. Neuron. 2013 Sep; 79(6):1094-108. doi: 10.1016/j.neuron.2013.07.037 PMID: 24050400
14. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013 Aug; 54(8):1420-7. doi: 10.2967/jnumed.112.117341 PMID: 23857514
15. McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, et al. Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements. J Nucl Med. 2009 Feb 17; 50(3):348-55. doi: 10.2967/jnumed.108.057612 PMID: 19223409
16. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996 Sep; 16(5):834-40. PMID: 8784228
17. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005 Nov; 25 (11):1528-47. PMID: 15944649
18. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005 Dec; 46(12):1959-72. PMID: 16330558
19. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993 Jan; 13(1):24-42. PMID: 8380178
20. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996 Dec; 4(3 Pt 1):153-8. PMID: 9345505
21. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014 Jun; 137(Pt 6):1762-71. doi: 10.1093/brain/awu064 PMID: 24681664
22. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med. 2016 Feb; 57(2):208-14. doi: 10.2967/jnumed.115.164848 PMID: 26541774
23. 11C]-2-(4′-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011Apr; 69(4):673-80. doi: 10.1002/ana.22320 PMID: 21337603